Literature DB >> 1974666

The current place of beta 2-agonists in the management of asthma.

N Svedmyr1.   

Abstract

Inhaled beta 2-stimulants are the most effective drugs for acute asthma attacks. This is probably due to the functional antagonism against a large variety of possible asthma mediators. A slight rebound increase of bronchial hyperreactivity 12 to 23 h after stopping regular treatment has been proposed. This finding is not well documented and must be further studied. There is no convincing evidence that tachyphylaxis of clinical importance to the bronchodilating effect occurs in asthmatics receiving normal doses of beta 2-receptor stimulants but cannot be totally excluded. Candidates for regular inhaled beta 2-agonist treatment always have inflammation in their airways and should be given inhaled steroids. Steroids not only seem to reduce airway inflammation and hyperreactivity but they also reverse beta 2-receptor subsensitivity in experimental studies. Patients on purely prophylactic antiasthmatic drugs should be instructed always to carry their beta 2-stimulants inhalers.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1974666     DOI: 10.1007/bf02718121

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  11 in total

1.  Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline.

Authors:  A S Vathenen; A J Knox; B G Higgins; J R Britton; A E Tattersfield
Journal:  Lancet       Date:  1988-03-12       Impact factor: 79.321

2.  Subsensitization of beta-adrenoceptors in airways and lymphocytes of healthy and asthmatic subjects.

Authors:  D P Tashkin; M E Conolly; R I Deutsch; K K Hui; M Littner; P Scarpace; I Abrass
Journal:  Am Rev Respir Dis       Date:  1982-02

3.  Clinical implications of drug-induced desensitization of the beta receptor after continuous oral use of terbutaline.

Authors:  W van den Berg; J G Leferink; J K Fokkens; J Kreukniet; R A Maes; P L Bruynzeel
Journal:  J Allergy Clin Immunol       Date:  1982-05       Impact factor: 10.793

4.  Airway hyperreactivity. Cholinergic and adrenergic receptors.

Authors:  N Svedmyr
Journal:  Eur J Respir Dis Suppl       Date:  1983

5.  Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline.

Authors:  J Kraan; G H Koëter; T W vd Mark; H J Sluiter; K de Vries
Journal:  J Allergy Clin Immunol       Date:  1985-10       Impact factor: 10.793

6.  Airway response to salbutamol: effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects.

Authors:  J E Harvey; A E Tattersfield
Journal:  Thorax       Date:  1982-04       Impact factor: 9.139

7.  Resistance to -adrenoceptor stimulants (a possible explanation for the rise in ashtma deaths).

Authors:  M E Conolly; D S Davies; C T Dollery; C F George
Journal:  Br J Pharmacol       Date:  1971-10       Impact factor: 8.739

8.  Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma.

Authors:  K F Kerrebijn; E E van Essen-Zandvliet; H J Neijens
Journal:  J Allergy Clin Immunol       Date:  1987-04       Impact factor: 10.793

9.  Slow-release oral salbutamol and aminophylline in nocturnal asthma: relation of overnight changes in lung function and plasma drug levels.

Authors:  A J Fairfax; W R McNabb; H J Davies; S G Spiro
Journal:  Thorax       Date:  1980-07       Impact factor: 9.139

Review 10.  Action of corticosteroids on beta-adrenergic receptors. Clinical aspects.

Authors:  N Svedmyr
Journal:  Am Rev Respir Dis       Date:  1990-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.